How it works
Non-selectively activates melanocortin receptors. MC1R activation drives melanogenesis; MC4R activation produces the appetite-suppressant and erectogenic effects.
Structure: Cyclic heptapeptide α-MSH analogue
Reported benefits
- Increased melanin production and tanning
- Appetite suppression
- Increased libido and erectile function
Practical considerations
- Case reports link it to changing moles and melanoma diagnoses
- Non-selective receptor action means side effects are the rule, not the exception
- Bremelanotide (PT-141) is the regulated alternative for sexual-health goals only
Side effects and risks
- Nausea and facial flushing
- Darkening of existing moles and freckles
- Spontaneous erections
- Melanoma risk concerns
Dosing overview
Loading 250–500 mcg daily, then weekly maintenance
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Research references
- Cardones & Grichnik, 2009 — α-MSH analogues and melanoma risk